Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ Origin: Appendix 5 \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$

Name of entity	
Carawine Resources Limited	

ABN 52 611 352 348

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- +Class of +securities issued or to be issued
- 1. Unlisted Incentive Options (Options)
- 2. Performance Rights (Rights)
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- 1. 500,000
- 2. 450,000 (being 225,000 Tranche 3 Performance Rights and 225,000 Tranche 4 Performance Rights as per the terms set out in the Company's prospectus dated 1 November 2017)

⁺ See chapter 19 for defined terms.

- Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if +securities, partly paid amount outstanding and due dates for payment; if +convertible the securities, conversion price and dates for conversion)
- 1. Issue of Options pursuant to CWX Employee Share Options Plan. Options each have an exercise price of \$0.40 and an expiry date of 12/02/2022. Exercise price is equivalent to 150% of the 30-day VWAP prior to the commencement date, vesting 12 months from the commencement date.
- 2. Grant of Rights pursuant to CWX Performance Rights Plan. payment is required upon the grant or vesting of Rights. Each Right is the right to one fully paid CWX ordinary share, subject to satisfaction of certain performance hurdles. Any Right does the that not satisfy performance hurdles by the relevant expiry date (which for the Tranche 3 Rights is 12/12/2020 and for the Tranche 4 Rights is 12/12/2021) shall The relevant performance lapse. hurdles are included in the ASX announcement dated 13 February

2018.

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

Do the *securities rank equally 4 in all respects from the +issue date with an existing +class of auoted +securities?

> If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- Options are not quoted. The Options do not entitle the holder to participate in dividends or new issues of securities. However, the Options will be adjusted in the event of a reconstruction of capital. Shares issued on exercise of Options shall rank equally in all respects with the existing fully paid ordinary shares then on issue.
- Rights are not quoted. The Rights not entitle the holder to participate in dividends or new issues of securities. Shares allocated upon vesting of Rights will rank equally from the date of allocation with ordinary CWX shares.
- Issue price or consideration 5

Nil

Purpose of the issue 6 (If issued as consideration for the acquisition of assets, clearly identify those assets)

- Issued to employee in accordance with employment agreement and the Employee Share Option Plan (ASX announcement 12/12/2017).
- 2. Issued to employee in accordance with employment agreement and CWX Performance Rights Plan (ASX announcement 12/12/2017).

Is the entity an +eligible entity 6a that has obtained security holder approval under rule 7.1A?

> If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

- The date the security holder 6b resolution under rule 7.1A was passed
- 6c under rule 7.1

No

N/A

Number of *securities issued N/A without security holder approval

Appendix 3B Page 3 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6.	Number of teamities issued	NT/A	
6е	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
	16	N7/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
-1		27/4	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	8,250,000	
_	+Iagua datas	Γ-10	
7	+Issue dates	12 February 2018	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		NT 1	-01
0	N	Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	52,710,743	Fully paid ordinary shares

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
2,289,257	Fully paid ordinary shares (escrowed until 12 December 2019)
18,222,939	Unlisted loyalty options (\$0.30, 12/12/2020)
500,000	Unlisted employee share options (\$0.30, 12/12/2021)
500,000	Unlisted employee share options (\$0.40, 12/02/2022)
250,000	Performance rights (exp 12/02/2019)
350,000	Performance rights (exp 12/12/2019)
775,000	(Performance rights exp 12/12/2020)
775,000	(Performance rights exp 12/12/2021)

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
	Uliel leiales	

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of	N/A

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	N/A
33	⁺ Issue	e date	N/A
		uotation of securitie	S oplying for quotation of securities
34	Type (tick o	of ⁺ securities one)	
(a)		⁺ Securities described in Part	1
(b)		All other *securities	
			nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es tha	t have ticked box 34(a)	
Addi	tional	securities forming a nev	v class of securities
Tick to docum		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36			securities, a distribution schedule of the additional umber of holders in the categories
		1 - 1,000 1,001 - 5,000	
		5,001 - 10,000 10,001 - 100,000 100,001 and over	
37		A copy of any trust deed for	the additional ⁺ securities

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)			
38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another +security, clearly identify that other +security)		
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number	⁺ Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Director/Company secretary)	Date:
Print name:		

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

⁺ See chapter 19 for defined terms.

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figurescapacity is calculated	Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	55,000,000 (on issue at listing)		
 Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid +ordinary securities cancelled during that 12 month period 	Nil		
"A"	55,000,000		

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	8,250,000	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule	
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	Nil	
Under an exception in rule 7.2		
Under rule 7.1A		
With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	Nil	
Step 4: Subtract "C" from ["A" x "I placement capacity under rule 7.1	B"] to calculate remaining	
"A" x 0.15	8,250,000	
Note: number must be same as shown in Step 2		
Subtract "C"	Nil	
Note: number must be same as shown in Step 3		
Total ["A" x 0.15] – "C"	8,250,000	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate "A", the base figue	ure from which the placement
"A"	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D" 0.10	
	Note: this value cannot be changed
Multiply "A" by 0.10	
Step 3: Calculate "E", the amount of 7.1A that has already been used	of placement capacity under rule
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.